Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

Plummer, Ruth
Verheul, Henk M.
de Vos, Filip Y. F. L.
Leunen, Karin
Molife, L. Rhoda
Rolfo, Christian
Grundtvig-Sørensen, Peter
de Grève, Jacques
Rottey, Sylvie
Jerusalem, Guy
Italiano, Antoine
Spicer, James
Dirix, Luc
Goessl, Carsten
Birkett, Joseph
Spencer, Stuart
Learoyd, Maria
Bailey, Christopher
Dean, Emma

January 2018

Introduction: The PARP inhibitor olaparib is efficacious as monotherapy and has potential applicatio...

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Vishwanathan, Karthick
Dickinson, Paul A.
So, Karen
Thomas, Karen
Chen, Yuh-Min
Carpeno, Javier
Dingemans, Anne-Marie C.
Kim, Hye Ryun
Kim, Joo-Hang
Krebs, Matthew G.
Yang, James Chih-Hsin
Bui, Bui
Weilert, Doris
Harvey, R. Donald

June 2018

AimsWe investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) ...

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Vishwanathan, Karthick
Dickinson, Paul A.
So, Karen
Thomas, Karen
Chen, Yuh-Min
Carpeno, Javier
Dingemans, Anne-Marie C.
Kim, Hye Ryun
Kim, Joo-Hang
Krebs, Matthew G.
Yang, James Chih-Hsin
Bui, Bui
Weilert, Doris
Harvey, R. Donald

June 2018

AimsWe investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) ...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies.

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen,
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

January 2016

PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Dirix, L.
Swaisland, H.
Verheul, H.M.
Rottey, S.
Leunen, K.
Jerusalem, G.
Rolfo, C.
Nielsen, D.
Molife, L.R.
Kristeleit, R.
Vos-Geelen, J.
Mau-Sorensen, M.
Soetekouw, P.
Herpen, C.M. van
Fielding, A.
So, K.
Bannister, W.
Plummer, R.

January 2016

PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Dirix, L.
Swaisland, H.
Verheul, H.M.
Rottey, S.
Leunen, K.
Jerusalem, G.
Rolfo, C.
Nielsen, D.
Molife, L.R.
Kristeleit, R.
Vos-Geelen, J.
Mau-Sorensen, M.
Soetekouw, P.
Herpen, C.M. van
Fielding, A.
So, K.
Bannister, W.
Plummer, R.

January 2016

Item does not contain fulltextPURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ri...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Dirix, L
Swaisland, H
Verheul, HMW
Rottey, S
Leunen, K
Jerusalem, G
Rolfo, C
Nielsen, D
Molife, LR
Kristeleit, R
de Vos-Geelen, J
Mau-Sorensen, M
Soetekouw, P
van Herpen, C
Fielding, A
So, K
Bannister, W
Plummer, R

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk MW
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L Rhoda
Kristeleit, Rebecca
Vos-Geelen, Judith de
Mau-Sørensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrat...

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

Plummer, R.
Verheul, H. M.
De Vos, F. Y. F. L.
Leunen, K.
Molife, L. R.
Rolfo, C.
Grundtvig-Sørensen, P.
De Grève, J.
Rottey, S.
JERUSALEM, Guy
Italiano, A.
Spicer, J.
Dirix, L.
Goessl, C.
Birkett, J.
Spencer, S.
Learoyd, M.
Bailey, C.
Dean, E.

January 2018

peer reviewedIntroduction: The PARP inhibitor olaparib is efficacious as monotherapy and has potenti...

Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

Hanna, Catherine
Kurian, Kathreena M.
Williams, Karin
Watts, Colin
Jackson, Alan
Carruthers, Ross
Strathdee, Karen
Cruickshank, Garth
Dunn, Laurence
Erridge, Sara
Godfrey, Lisa
Jefferies, Sarah
McBain, Catherine
Sleigh, Rebecca
McCormick, Alex
Pittman, Marc
Halford, Sarah
Chalmers, Anthony J.

December 2020

Background: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and tem...

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

Plummer, Ruth
Verheul, Henk M.
de Vos, Filip Y. F. L.
Leunen, Karin
Molife, L. Rhoda
Rolfo, Christian
Grundtvig-Sørensen, Peter
de Grève, Jacques
Rottey, Sylvie
Jerusalem, Guy
Italiano, Antoine
Spicer, James
Dirix, Luc
Goessl, Carsten
Birkett, Joseph
Spencer, Stuart
Learoyd, Maria
Bailey, Christopher
Dean, Emma

January 2018

Introduction: The PARP inhibitor olaparib is efficacious as monotherapy and has potential applicatio...

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Vishwanathan, Karthick
Dickinson, Paul A.
So, Karen
Thomas, Karen
Chen, Yuh-Min
Carpeno, Javier
Dingemans, Anne-Marie C.
Kim, Hye Ryun
Kim, Joo-Hang
Krebs, Matthew G.
Yang, James Chih-Hsin
Bui, Bui
Weilert, Doris
Harvey, R. Donald

June 2018

AimsWe investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) ...

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Vishwanathan, Karthick
Dickinson, Paul A.
So, Karen
Thomas, Karen
Chen, Yuh-Min
Carpeno, Javier
Dingemans, Anne-Marie C.
Kim, Hye Ryun
Kim, Joo-Hang
Krebs, Matthew G.
Yang, James Chih-Hsin
Bui, Bui
Weilert, Doris
Harvey, R. Donald

June 2018

AimsWe investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) ...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies.

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen,
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

January 2016

PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Dirix, L.
Swaisland, H.
Verheul, H.M.
Rottey, S.
Leunen, K.
Jerusalem, G.
Rolfo, C.
Nielsen, D.
Molife, L.R.
Kristeleit, R.
Vos-Geelen, J.
Mau-Sorensen, M.
Soetekouw, P.
Herpen, C.M. van
Fielding, A.
So, K.
Bannister, W.
Plummer, R.

January 2016

PURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors:Results of Two Phase I Open-label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk M. W.
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L. Rhoda
Kristeleit, Rebecca
de Vos-Geelen, Judith
Mau-Sorensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Dirix, L.
Swaisland, H.
Verheul, H.M.
Rottey, S.
Leunen, K.
Jerusalem, G.
Rolfo, C.
Nielsen, D.
Molife, L.R.
Kristeleit, R.
Vos-Geelen, J.
Mau-Sorensen, M.
Soetekouw, P.
Herpen, C.M. van
Fielding, A.
So, K.
Bannister, W.
Plummer, R.

January 2016

Item does not contain fulltextPURPOSE: The metabolism of olaparib, a potent inhibitor of poly(ADP-ri...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies

Dirix, L
Swaisland, H
Verheul, HMW
Rottey, S
Leunen, K
Jerusalem, G
Rolfo, C
Nielsen, D
Molife, LR
Kristeleit, R
de Vos-Geelen, J
Mau-Sorensen, M
Soetekouw, P
van Herpen, C
Fielding, A
So, K
Bannister, W
Plummer, R

October 2016

Purpose: The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with d...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies

Dirix, Luc
Swaisland, Helen
Verheul, Henk MW
Rottey, Sylvie
Leunen, Karin
Jerusalem, Guy
Rolfo, Christian
Nielsen, Dorte
Molife, L Rhoda
Kristeleit, Rebecca
Vos-Geelen, Judith de
Mau-Sørensen, Morten
Soetekouw, Patricia
van Herpen, Carla
Fielding, Anitra
So, Karen
Bannister, Wendy
Plummer, Ruth

October 2016

The metabolism of olaparib, a potent inhibitor of poly(ADP-ribose) polymerase (PARP) with demonstrat...

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

Plummer, R.
Verheul, H. M.
De Vos, F. Y. F. L.
Leunen, K.
Molife, L. R.
Rolfo, C.
Grundtvig-Sørensen, P.
De Grève, J.
Rottey, S.
JERUSALEM, Guy
Italiano, A.
Spicer, J.
Dirix, L.
Goessl, C.
Birkett, J.
Spencer, S.
Learoyd, M.
Bailey, C.
Dean, E.

January 2018

peer reviewedIntroduction: The PARP inhibitor olaparib is efficacious as monotherapy and has potenti...

Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

Hanna, Catherine
Kurian, Kathreena M.
Williams, Karin
Watts, Colin
Jackson, Alan
Carruthers, Ross
Strathdee, Karen
Cruickshank, Garth
Dunn, Laurence
Erridge, Sara
Godfrey, Lisa
Jefferies, Sarah
McBain, Catherine
Sleigh, Rebecca
McCormick, Alex
Pittman, Marc
Halford, Sarah
Chalmers, Anthony J.

December 2020

Background: The poly(ADP-ribose) polymerase (PARP) inhibitor olaparib potentiated radiation and tem...

Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours

Plummer, Ruth
Verheul, Henk M.
de Vos, Filip Y. F. L.
Leunen, Karin
Molife, L. Rhoda
Rolfo, Christian
Grundtvig-Sørensen, Peter
de Grève, Jacques
Rottey, Sylvie
Jerusalem, Guy
Italiano, Antoine
Spicer, James
Dirix, Luc
Goessl, Carsten
Birkett, Joseph
Spencer, Stuart
Learoyd, Maria
Bailey, Christopher
Dean, Emma

January 2018

Introduction: The PARP inhibitor olaparib is efficacious as monotherapy and has potential applicatio...

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Vishwanathan, Karthick
Dickinson, Paul A.
So, Karen
Thomas, Karen
Chen, Yuh-Min
Carpeno, Javier
Dingemans, Anne-Marie C.
Kim, Hye Ryun
Kim, Joo-Hang
Krebs, Matthew G.
Yang, James Chih-Hsin
Bui, Bui
Weilert, Doris
Harvey, R. Donald

June 2018

AimsWe investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) ...

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Vishwanathan, Karthick
Dickinson, Paul A.
So, Karen
Thomas, Karen
Chen, Yuh-Min
Carpeno, Javier
Dingemans, Anne-Marie C.
Kim, Hye Ryun
Kim, Joo-Hang
Krebs, Matthew G.
Yang, James Chih-Hsin
Bui, Bui
Weilert, Doris
Harvey, R. Donald

June 2018

AimsWe investigated the effects of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampicin) ...

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies

Abstract

Extracted data

Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies

Abstract

Extracted data

Related items

Related items